<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828410</url>
  </required_header>
  <id_info>
    <org_study_id>H-33890</org_study_id>
    <nct_id>NCT02828410</nct_id>
  </id_info>
  <brief_title>Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA</brief_title>
  <official_title>Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Ileal Pouch-Anal Anastomosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Entera Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label trial to test the hypothesize that serum bovine immunoglobulin protein
      isolate (SBI) will improve the nutritional status and quality of life (QOL) of patients with
      an ileal pouch anal anastomosis (IPAA) and symptoms of pouchitis. Subjects with symptomatic
      IPAA will receive two packets of EnteraGam twice daily (total daily dose of 20 g SBI) for up
      to 24 weeks. The primary objective of this study is to determine whether SBI therapy leads to
      improved nutritional status and QOL. A secondary objective is to evaluate SBI in the
      management of their disease, including impact on clinical symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study involving patients who are status post ileal pouch-anal
      anastomosis age 18 and 75 who receive care at Boston Medical Center's Center for Digestive
      Disorders (CDD). There is no randomization or use of placebo in this study and patients will
      be recruited sequentially. This is an open-label, single center study evaluating the
      effectiveness of SBI or EnteraGam (10.0 g twice per day) on nutritional status and quality of
      life in patients with ileal pouch-anal anastomosis.

      Nutritional status and inflammation be assessed by measuring CBC with differential, vitamin
      D, vitamin B12, pre-albumin, albumin, ferritin, ESR, CRP, alpha-1-antitrypsin, and fecal
      calprotectin levels at screening, Day 84, and Day 168. Stool samples from these same time
      points will also be frozen and stored until the end of the study for potential fecal
      microbiome analysis depending on the results of other outcome measures.

      The effect of SBI on a subject's quality of life (QoL) will be evaluated using the Short
      Inflammatory Bowel Disease Questionnaire and Cleveland Global Quality of Life scores at
      baseline, Day 28, Day 84, and End of Study.

      The short form of disease specific QoL (s-IBDQ) includes 10 questions derived from the 32
      questions IBDQ concerning QoL. It covers four items: bowel symptoms, systemic symptoms,
      emotional, and social functions. The total score ranges from 10 (worst health) to 70 (best
      health).

      The Cleveland Global Quality of Life (CGOL) score is an instrument specifically designed for
      patients with ileal pouches. Subjects will be asked to rate each of three items (current QOL,
      current quality of health, and current energy level) on a scale of 0-10, 0 being the worst
      and 10 the best. The sum of the three scores divided by 30 will provide the CGQL score.

      The Modified Pouchitis Disease Activity Index (mPDAI) will be used to evaluate for pouchitis
      and assess the overall disease activity for each subject at baseline pouchoscopy. This
      modified diagnostic instrument consists of two component scores: clinical symptoms (range 0-6
      points) and endoscopic appearence (range 0-6 points). Follow-up pouchoscopy is not part of
      the study protocol. However, if a patient warrants follow-up pouchoscopy at any point during
      the study period based on standard of care (most likley due to worsening or non-responsive
      symptoms), then the mPDAI at follow-up pouchoscopy will also be calculated and included in
      outcomes analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre-albumin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin D</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin B12</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ferritin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Short Inflammatory Bowel Disease Quality of Life Score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cleveland Global Quality of Life Score</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Bowel Movements</measure>
    <time_frame>6 months</time_frame>
    <description>Average number of nightly nocturnal bowel movements over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Medications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Cramping</measure>
    <time_frame>6 months</time_frame>
    <description>Number of days experiencing abdominal cramping over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency of Bowel Movements</measure>
    <time_frame>6 months</time_frame>
    <description>Average Bristol Stool Scale score for bowel movements during the previous week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of incontinence episodes over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR</measure>
    <time_frame>6 Months</time_frame>
    <description>Sedimentation Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>6 Months</time_frame>
    <description>C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-antitrypsin</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Movements</measure>
    <time_frame>6 Months</time_frame>
    <description>Average number of daily bowel movements over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Urgency</measure>
    <time_frame>6 Months</time_frame>
    <description>Average number of days with fecal urgency over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Pouchitis Disease Activity Index Score</measure>
    <time_frame>6 Months</time_frame>
    <description>When applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rectal Bleeding</measure>
    <time_frame>6 Months</time_frame>
    <description>Average number of days with rectal bleeding over the past week</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pouchitis</condition>
  <condition>Irritable Pouch Syndrome</condition>
  <arm_group>
    <arm_group_label>SBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum bovine immunoglobulin protein isolate (SBI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SBI</intervention_name>
    <description>Serum bovine immunoglobulin protein isolate 10 g twice per day</description>
    <arm_group_label>SBI</arm_group_label>
    <other_name>EnteraGam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female between the ages of 18-75 years, inclusive.

          -  Patient has history of UC or Crohn's disease (CD) diagnosed by standard clinical,
             radiographic, endoscopic, and histopathological criteria.

          -  Patient has undergone total proctocolectomy and IPAA surgery a minimum of 6 months
             prior to screening.

          -  Patient has symptoms suggestive of pouchitis including frequent bowel movements of
             greater than or equal to seven per day (â‰¥7 per day), and one or more of the following:
             daily rectal bleeding, fecal urgency, abdominal cramps, or fever &gt;37.8oC).

          -  Patient is capable of understanding the requirements of the study and has signed /
             dated an IRB approved informed consent form.

        Exclusion Criteria:

          -  Patient cannot or will not provide written informed consent.

          -  Patient has a known allergy or hypersensitivity to beef, beef products, or any
             ingredient used in EnteraGam.

          -  Patient has clinical signs and symptoms of an active infection.

          -  Patient is on antibiotic therapy (other than for pouchitis treatment) at any time in
             the 30 days prior to screening.

          -  Patient has active alcohol or drug abuse or psychiatric disorders felt to preclude his
             / her ability to complete the study.

          -  Patient who, in the opinion of the investigator, has a poorly controlled /
             uncontrolled significant medical condition that would interfere with the study.

          -  Positive stool test (PCR) for C. difficile.

          -  Use of antidiarrheal medications (ADM). - Exception: patients who, in the opinion of
             the Investigator, are on stable treatment with ADMs may be enrolled provided that the
             administration schedule is intended to be maintained or decreased during the study and
             the subject has been on stable treatment with ADMs for at least 30 days prior to
             screening; otherwise, these agents are prohibited in the study.

          -  Use of an investigational product or participation in a clinical trial within the past
             three months.

          -  Use of a biologic (e.g., infliximab, adalimumab) within the last 3 months.

          -  Patient is pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Farraye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Francis Farraye, MD</investigator_full_name>
    <investigator_title>BMC Investigator</investigator_title>
  </responsible_party>
  <keyword>serum bovine immunoglobulin protein isolate</keyword>
  <keyword>IPAA</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pouchitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

